...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals
【24h】

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

机译：用MVA-HIV-1 nef进行治疗性疫苗接种会在慢性HIV-1感染者中引起Nef特异性T辅助细胞应答

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Vaccination is currently considered as an additional therapeutic approach to stimulate HIV-specific immune response in subjects that could not naturally control HIV. Ten chronically HIV infected individuals have been vaccinated with a modified vaccinia Ankara (MVA)-HIV- 1(LAI)-nef vector in order to assess safety and immunogenicity. No significant adverse effects were observed during the course of vaccination indicating for the first time that the highly attenuated vaccinia-vir-us vector MVA is safe in HIV-1 infected individuals. We observed a CD4 T-cell response to Nef in the majority of vaccinated chronically HIV infected individuals. In two subjects CD4 T-cell response was directed to previously unidentified Nef epitopes. The strong Nef-specific CD4 T-cell response elicited by MVA-nef vaccination provides a rationale for immunotherapeutic interventions in HIV infected individuals with suppressed CD4 T-cell responses. Moreover, the CD4 T-cell response elicited was comparable with that usually detected in long-term non-progressor (LTNP) suggesting an improvement in the immunological status of the vaccinated subjects. Furthermore, the new putative CD4 epitopes described here hold promise as important tools for epitope-based vaccination
机译：疫苗接种目前被认为是在无法自然控制HIV的受试者中刺激HIV特异性免疫反应的另一种治疗方法。为了评估安全性和免疫原性，已经用改良的牛痘安卡拉（MVA）-HIV-1（LAI）-nef疫苗接种了10个慢性HIV感染者。在疫苗接种过程中未观察到明显的不良反应，这首次表明高度减毒的痘苗病毒载体MVA在感染HIV-1的个体中是安全的。我们观察到大多数接种过慢性HIV感染的个体对Nef的CD4 T细胞反应。在两名受试者中，CD4 T细胞反应针对先前未鉴定的Nef表位。由MVA-nef疫苗接种引起的强烈的Nef特异性CD4 T细胞反应为CD4 T细胞反应受到抑制的HIV感染者提供了免疫治疗干预的依据。此外，引起的CD4 T细胞反应与长期非进展者（LTNP）中通常检测到的CD4 T细胞反应相当，这表明接种者的免疫状况得到改善。此外，此处描述的新的假定CD4表位有望作为基于表位的疫苗接种的重要工具

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号